Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

164.84 0.76 −0.46%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
−139×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 3 3 5

+8 more TTM periods

ROE
(25.98%) (26.39%) (26.38%) (12.19%)
ROA
(19.72%) (20.36%) (20.09%) (9.10%)
ROIC
(26.07%) (26.89%) (28.00%) (9.79%)
Return on Tangible Assets
(35.78%) (37.21%) (38.54%) (18.32%)
Average Days of Receivables
82.73 79.24 78.12 76.67
Free Cash Flow per Share
(0.21) (0.60) (0.68) (0.77)
Free Cash Flow
(12.20) (35.09) (39.06) (44.22)
Capital Expenditures
(11.25) (26.29) (24.27) (23.09)
Other line items
Cash ROIC
(1.18%) (3.46%) (3.89%) (3.98%)
Accounts Receivable Turnover
5.52 5.77 5.99 6.06
Accounts Payable Turnover
7.80 6.91 5.94 7.01
Inventory Turnover
2.07 1.98 1.84 1.76
Average Days of Payables
54.59 57.85 80.38 66.78
Days of Inventory on Hand
169.17 188.44 207.50 214.49
Tax Rate
(0.02) (0.03) (0.03) 0.01
Research and Development Expense of Revenue
29.15% 29.46% 29.68% 30.54%
Selling, General and Administrative Expense of Revenue
63.10% 64.21% 65.38% 65.14%
Share Based Compensation of Revenue
13.09% 12.58% 12.46% 12.61%
Interest Coverage
(39.42) (43.24) (43.06) (17.47)
Operating CF/Net income
0.01 0.05 0.08 0.24
Depreciation/Fixed assets
0.40 0.39 0.35 0.32
Capex/Depreciation
(0.25) (0.60) (0.62) (0.65)
Revenue per Share
10.42 9.50 8.87 8.19
Operating CF per Share
(0.02) (0.15) (0.26) (0.37)
Capex per Share
(0.19) (0.45) (0.42) (0.40)
Capex to Sales
0.02 0.05 0.05 0.05

Fold the line items

Columns are period end dates